3/26
09:16 am
actu
Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer [Seeking Alpha]
Medium
Report
Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer [Seeking Alpha]
3/17
08:02 am
actu
Actuate Therapeutics (NASDAQ: ACTU) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $20.00 price target on the stock.
Low
Report
Actuate Therapeutics (NASDAQ: ACTU) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $20.00 price target on the stock.
2/25
09:34 am
actu
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer [Yahoo! Finance]
Low
Report
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer [Yahoo! Finance]
2/25
08:00 am
actu
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
High
Report
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer
2/6
08:00 am
actu
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February
Medium
Report
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February
1/7
08:35 am
actu
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer [Yahoo! Finance]
Medium
Report
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer [Yahoo! Finance]
1/7
08:00 am
actu
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
Medium
Report
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer